Visium Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Visium Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-9,200	Closed	-$958K	–	870
2015 Q3	$958K	Buy	9,200 +1,700	+23%	+$218K	0.01%	513
2015 Q2	$926K	Sell	7,500 -3,818	-34%	-$481K	0.01%	535
2015 Q1	$1.33M	Buy	+11,318	New	+$1.36M	0.02%	486
2014 Q4	–	Sell	-97,903	Closed	-$11M	–	1213
2014 Q3	$11M	Buy	97,903 +47,903	+96%	+$4.56M	0.16%	129
2014 Q2	$4.73M	Buy	+50,000	New	+$3.51M	0.07%	239

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Visium Asset Management's VRTX Position: Q4 2015 in Review

Visium Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 9,200 shares — an estimated $958K sold.

Visium Asset Management first reported a position in VRTX in Q2 2014 and held it in 5 quarters. The position peaked at $11M in Q3 2014. 517 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

Visium Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Visium Asset Management sold 9,200 Vertex Pharmaceuticals shares in Q4 2015, an estimated $958K.
Visium Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Visium Asset Management's Vertex Pharmaceuticals position peaked at $11M in Q3 2014.
517 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Visium Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.